查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1722477

2025 年至 2033 年药物警戒和药物安全软体市场报告（按功能、交付模式、最终用户和地区）

Pharmacovigilance and Drug Safety Software Market Report by Functionality, Delivery Mode, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 134 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球药物警戒与药物安全软体市场规模达 2.142 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 3.508 亿美元，2025-2033 年期间的成长率 (CAGR) 为 5.63%。慢性病在人群中的日益普遍、药品商业化的严格监管实施以及软体功能和用户友好界面的不断进步是推动市场发展的一些主要因素。

药物警戒和药物安全软体是指旨在简化和加强对药物不良反应 (ADR) 和其他药物相关安全问题的监测、分析和报告的专门电脑程式。这些软体系统在药物警戒领域中发挥着至关重要的作用，致力于确保药物的安全有效使用。这些软体解决方案使製药公司、监管机构和医疗保健专业人员能够有效地收集、管理和分析大量与药物安全相关的资料。它们还有助于检测潜在的风险和模式，从而及时采取干预和风险缓解策略。

药物警戒和药物安全软体市场受到临床研究和外包公司越来越多地采用这些软体解决方案的推动。这些组织认识到强大的药物警戒系统对于确保药物在开发和上市后监测中的安全性和有效性的重要性。此外，慢性病的日益普及也促进了市场的成长。随着需要长期服药的患者数量的增加，对有效的药物安全监测和管理的需求也随之增加。此外，世界各国政府对药品商业化实施了严格的监管，导致药品安全法规更加复杂，进一步推动了需求。此外，尖端技术的出现也促进了药物警戒和药物安全软体的轻鬆采用。此外，软体功能和使用者友善介面的不断进步使组织更容易实施这些解决方案并将其整合到现有的工作流程中，从而对市场产生积极影响。

药物警戒与药物安全软体市场趋势/驱动因素：

製药业的扩张

製药业的发展对全球药物警戒（PV）和药品安全软体市场产生了重大影响。随着製药业的扩张，新药和新疗法的开发也不断增加。这导致对 PV 和药物安全软体的需求更大，以监测、分析和管理不良事件，从而导致对该软体的需求增加。此外，製药业的扩张导致资料量和复杂性的增加，需要复杂的软体来管理和分析资料。这推动了 PV 和药物安全软体中人工智慧和机器学习的开发和应用，以有效处理此类复杂的数据集。此外，药物警戒和药物安全软体有助于管理这些风险，而日益增长的风险管理需求正在推动该市场的需求。

药物不良反应发生率不断上升

药物不良反应（ADR）发生率的不断上升对全球药物警戒和药物安全软体市场产生了重大影响。报告的药品不良反应数量不断增加，对强大的药物警戒系统和软体解决方案的需求也随之增加，以确保市场上药品的安全性和有效性。药物不良反应会对患者的健康和福祉造成严重后果，导致住院、额外的医疗费用，甚至死亡。因此，世界各地的监管机构都实施了严格的指导方针和法规，要求製药公司有效监测和报告药物不良反应。同时，全球药物警戒和药物安全软体市场经历了显着增长，直接应对了药品不良反应（ADR）的不断上升，因为提供这些软体解决方案的公司不断创新，提供先进的工具和功能，可以有效地处理大量不良事件资料。

医疗支出不断增加

随着全球医疗保健支出的持续成长，人们越来越重视优化病人安全和提高医疗保健的整体品质。药物警戒和药物安全软体在实现这些目标方面发挥着至关重要的作用，确保有效监测、评估和管理药物不良反应 (ADR) 和其他药物相关问题。随着医疗支出的增加，人们越来越关注病人安全。药物警戒软体为医疗保健组织和监管机构提供了监测和预防药物不良反应的工具，从而减轻了与药物相关危害相关的经济负担。此外，医疗支出的成长使得资源优化成为必要。此外，药物警戒软体能够有效管理不良事件资料，简化报告和分析流程。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球药物警戒与药品安全软体市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依功能

  • 不良事件通报软体
  • 药品安全审计软体
  • 问题追踪软体
  • 完全整合的软体

第七章：市场区隔：依交付方式

  • 本地
  • 基于云端

第八章：市场区隔：按最终用户

  • 製药和生物技术公司
  • 合约研究组织
  • 业务流程外包公司
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第十章：SWOT分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Ab Cube
    • Anju Software Inc.
    • ArisGlobal LLC
    • Cognizant
    • Ennov Solutions Inc.
    • Extedo GmbH
    • Max Application
    • Oracle Corporation
    • Sarjen Systems Pvt Ltd
    • Sparta Systems Inc. (Honeywell International Inc.)
    • Tata Consultancy Services Limited
    • United BioSource LLC
    • Wipro Limited
Product Code: SR112025A5030

The global pharmacovigilance and drug safety software market size reached USD 214.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 350.8 Million by 2033, exhibiting a growth rate (CAGR) of 5.63% during 2025-2033. The growing prevalence of chronic diseases among the masses, the implementation of strict regulations on the commercialization of drugs, and continual advancements in software capabilities and user-friendly interfaces are some of the major factors propelling the market.

Pharmacovigilance and drug safety software refers to specialized computer programs designed to streamline and enhance the monitoring, analysis, and reporting of adverse drug reactions (ADRs) and other drug-related safety concerns. These software systems play a crucial role in the field of pharmacovigilance, which is dedicated to ensuring the safe and effective use of medications. These software solutions enable pharmaceutical companies, regulatory authorities, and healthcare professionals to efficiently collect, manage, and analyze large volumes of data pertaining to drug safety. They also facilitate the detection of potential risks and patterns, allowing for timely intervention and risk mitigation strategies.

The pharmacovigilance and drug safety software market is driven by the increasing adoption of these software solutions by clinical research and outsourcing companies. These organizations recognize the importance of robust pharmacovigilance systems to ensure the safety and efficacy of drugs in development and post-marketing surveillance. Moreover, the growing prevalence of chronic diseases is also contributing to the growth of the market. As the number of patients requiring long-term medication increases, so does the need for effective drug safety monitoring and management. Apart from this, governments worldwide are imposing strict regulations on the commercialization of drugs, leading to increased complexity in drug safety regulations, further impelling the demand. Besides, the availability of cutting-edge technology is facilitating the easy adoption of pharmacovigilance and drug safety software. Furthermore, continual advancements in software capabilities and user-friendly interfaces make it easier for organizations to implement and integrate these solutions into their existing workflows, thus impacting the market favorably.

Pharmacovigilance and Drug Safety Software Market Trends/Drivers:

Expansion of the Pharmaceutical Industry

The development of the pharmaceutical industry is having a significant influence on the global pharmacovigilance (PV) and drug safety software market. As the pharmaceutical industry expands, there has been an increase in the development of new drugs and therapies. This leads to a greater need for PV and drug safety software to monitor, analyze, and manage adverse events, leading to an increase in demand for this software. Moreover, the pharmaceutical industry's expansion has led to a rise in data volume and complexity, requiring sophisticated software for managing and analyzing data. This is driving the development and adoption of AI and machine learning within PV and drug safety software to handle, such complex datasets effectively. Also, pharmacovigilance and drug safety software help manage these risks, and the growing need for risk management is driving demand in this market.

Growing Incidence of Adverse Drug Reactions

The increasing incidence of adverse drug reactions (ADRs) is significantly influencing the global pharmacovigilance and drug safety software market. The raising number of reported ADRs has created a greater need for robust pharmacovigilance systems and software solutions to ensure the safety and efficacy of drugs in the market. Adverse drug reactions can have serious consequences on patient health and well-being, leading to hospitalizations, additional medical costs, and even fatalities. Therefore, regulatory authorities worldwide have implemented stringent guidelines and regulations for pharmaceutical companies to monitor and report ADRs effectively. Along with this, the global pharmacovigilance and drug safety software market has experienced significant growth as a direct response to the rising incidence of ADRs since companies offering these software solutions are continuously innovating to provide advanced tools and functionalities that can handle large volumes of adverse event data efficiently.

The Increasing Healthcare Expenditure

As healthcare expenditure continues to rise globally, there is a growing emphasis on optimizing patient safety and improving the overall quality of healthcare delivery. Pharmacovigilance and drug safety software play a crucial role in achieving these objectives by ensuring the effective monitoring, assessment, and management of adverse drug reactions (ADRs) and other drug-related problems. With higher healthcare spending, there has been a growing focus on patient safety. Pharmacovigilance software provides healthcare organizations and regulatory authorities with the tools to monitor and prevent ADRs, thereby reducing the economic burden associated with medication-related harm. Moreover, healthcare expenditure growth necessitates the optimization of resources. Furthermore, pharmacovigilance software enables the efficient management of adverse event data, streamlining the reporting and analysis processes.

Pharmacovigilance and Drug Safety Software Industry Segmentation:

Breakup by Functionality:

  • Adverse Event Reporting Software
  • Drug Safety Audits Software
  • Issue Tracking Software
  • Fully Integrated Software

Adverse event reporting software dominates the market

Adverse event reporting software dominates the market as it is a critical aspect of regulatory compliance in the healthcare and pharmaceutical industries. It offers robust data management capabilities, allowing efficient collection, organization, and analysis of adverse event data. It enables the identification of patterns, trends, and potential safety issues associated with specific products or interventions. This data-driven approach helps pharmaceutical companies, healthcare providers, and regulatory agencies make informed decisions regarding product safety and risk mitigation strategies. Additionally, it provides a systematic and standardized approach to capturing and reporting these events, ensuring compliance with regulatory requirements. It provides a centralized platform for healthcare professionals, drug safety experts, and other stakeholders involved in adverse event reporting. Additionally, the software can scale to handle large volumes of adverse event data, ensuring its effectiveness even for organizations with extensive reporting requirements.

Breakup by Delivery Mode:

  • On-premises
  • Cloud-based

On- premises delivery holds the largest share in the market

On-premises deployment holds the largest share of the market as it provides organizations with a higher level of control and security over their data. It offers greater flexibility for customization and integration with existing systems. Organizations can tailor the software to their specific requirements and integrate it seamlessly with other on-premises applications or infrastructure. This level of customization and integration is beneficial for organizations with complex IT environments or unique business processes. The deployment allows organizations to maintain data sovereignty by ensuring that sensitive data remains within the borders of their own country. Moreover, the widespread adoption of on-premises software help eliminate the potential performance issues related to network latency or dependence on internet connectivity. Also, it allows organizations to maintain compliance and meet regulatory standards more easily.

Breakup by End User:

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Business Process Outsourcing Firms
  • Others

Contract research organizations hold the largest share in the market

CROs hold a significant position and are the leading users of the market's products or services. They specialize in providing comprehensive research services, allowing pharmaceutical and biotech companies to outsource various aspects of their R&D activities. This outsourcing model offers numerous benefits, including access to specialized expertise, reduced operational costs, and increased efficiency in trial execution. They provide in-depth knowledge of industry best practices, regulatory requirements, and emerging trends which makes it an attractive choice for companies seeking reliable partners to navigate complex research processes and achieve successful outcomes. They also have the ability to scale their resources and infrastructure according to project requirements, enabling them to support both small-scale studies and large multinational trials. They can provide expertise in risk management, data integrity, and compliance, helping companies navigate the complex regulatory landscape and mitigate potential pitfalls.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest pharmacovigilance and drug safety software market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has a robust and well-established pharmaceutical industry, with numerous companies involved in drug discovery, development, and commercialization. The region is at the forefront of technological innovation, including advancements in healthcare and information technology. The region has a robust IT infrastructure, a favorable investment climate for research and development, and a strong focus on adopting digital solutions. North American pharmaceutical companies and research institutions often collaborate with academic institutions, healthcare providers, and technology companies to drive innovation in pharmacovigilance and drug safety. These collaborations foster the development and adoption of state-of-the-art software solutions, further enhancing North America's dominance in the market. Additionally, the region has stringent regulatory requirements for drug safety and pharmacovigilance is another significant factor responsible for impelling the market across the North America region.

Competitive Landscape:

Top companies in the market are investing in research and development activities to create advanced pharmacovigilance and drug safety software solutions. These software platforms are designed to capture, process, analyze, and report adverse events, safety data, and other relevant information related to pharmaceutical products and medical interventions. Various companies offer flexible and scalable software platforms that can be tailored to meet the unique needs of pharmaceutical companies, CROs, and healthcare institutions. Additionally, companies leverage advanced data analytics techniques, such as artificial intelligence (AI) and machine learning (ML), to analyze large volumes of safety data and identify potential safety signals. These analytics capabilities help in the early detection of adverse events, signal management, risk assessment, and trend analysis.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Ab Cube
  • Anju Software Inc.
  • ArisGlobal LLC
  • Cognizant
  • Ennov Solutions Inc.
  • Extedo GmbH
  • Max Application
  • Oracle Corporation
  • Sarjen Systems Pvt Ltd
  • Sparta Systems Inc. (Honeywell International Inc.)
  • Tata Consultancy Services Limited
  • United BioSource LLC
  • Wipro Limited.

Key Questions Answered in This Report

  • 1.What was the size of the global pharmacovigilance and drug safety software market in 2024?
  • 2.What is the expected growth rate of the global pharmacovigilance and drug safety software market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global pharmacovigilance and drug safety software market?
  • 4.What are the key factors driving the global pharmacovigilance and drug safety software market?
  • 5.What is the breakup of the global pharmacovigilance and drug safety software market based on the functionality?
  • 6.What is the breakup of the global pharmacovigilance and drug safety software market based on the delivery mode?
  • 7.What is the breakup of the global pharmacovigilance and drug safety software market based on the end user?
  • 8.What are the key regions in the global pharmacovigilance and drug safety software market?
  • 9.Who are the key players/companies in the global pharmacovigilance and drug safety software market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmacovigilance and Drug Safety Software Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Functionality

  • 6.1 Adverse Event Reporting Software
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Drug Safety Audits Software
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Issue Tracking Software
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Fully Integrated Software
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Delivery Mode

  • 7.1 On-premises
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cloud-based
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Pharmaceutical and Biotechnology Companies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Contract Research Organizations
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Business Process Outsourcing Firms
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Ab Cube
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Anju Software Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 ArisGlobal LLC
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Cognizant
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Ennov Solutions Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Extedo GmbH
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Max Application
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Oracle Corporation
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sarjen Systems Pvt Ltd
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Sparta Systems Inc. (Honeywell International Inc.)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Tata Consultancy Services Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 United BioSource LLC
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
    • 14.3.13 Wipro Limited
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pharmacovigilance and Drug Safety Software Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Pharmacovigilance and Drug Safety Software Market: Breakup by Functionality (in %), 2024
  • Figure 5: Global: Pharmacovigilance and Drug Safety Software Market: Breakup by Delivery Mode (in %), 2024
  • Figure 6: Global: Pharmacovigilance and Drug Safety Software Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Pharmacovigilance and Drug Safety Software Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Pharmacovigilance and Drug Safety Software (Adverse Event Reporting Software) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Pharmacovigilance and Drug Safety Software (Adverse Event Reporting Software) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Pharmacovigilance and Drug Safety Software (Drug Safety Audits Software) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Pharmacovigilance and Drug Safety Software (Drug Safety Audits Software) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Pharmacovigilance and Drug Safety Software (Issue Tracking Software) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Pharmacovigilance and Drug Safety Software (Issue Tracking Software) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Pharmacovigilance and Drug Safety Software (Fully Integrated Software) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Pharmacovigilance and Drug Safety Software (Fully Integrated Software) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Pharmacovigilance and Drug Safety Software (On-premises) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Pharmacovigilance and Drug Safety Software (On-premises) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Pharmacovigilance and Drug Safety Software (Cloud-based) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Pharmacovigilance and Drug Safety Software (Cloud-based) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Pharmacovigilance and Drug Safety Software (Pharmaceutical and Biotechnology Companies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Pharmacovigilance and Drug Safety Software (Pharmaceutical and Biotechnology Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Pharmacovigilance and Drug Safety Software (Contract Research Organizations) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Pharmacovigilance and Drug Safety Software (Contract Research Organizations) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Pharmacovigilance and Drug Safety Software (Business Process Outsourcing Firms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Pharmacovigilance and Drug Safety Software (Business Process Outsourcing Firms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Pharmacovigilance and Drug Safety Software (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Pharmacovigilance and Drug Safety Software (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia-Pacific: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia-Pacific: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Pharmacovigilance and Drug Safety Software Market: Breakup by Country (in %), 2024
  • Figure 76: Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Pharmacovigilance and Drug Safety Software Industry: SWOT Analysis
  • Figure 78: Global: Pharmacovigilance and Drug Safety Software Industry: Value Chain Analysis
  • Figure 79: Global: Pharmacovigilance and Drug Safety Software Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmacovigilance and Drug Safety Software Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Breakup by Functionality (in Million USD), 2025-2033
  • Table 3: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Breakup by Delivery Mode (in Million USD), 2025-2033
  • Table 4: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Pharmacovigilance and Drug Safety Software Market: Competitive Structure
  • Table 7: Global: Pharmacovigilance and Drug Safety Software Market: Key Players